Feb. 17 at 1:19 PM
$INBS Headline:
$INBS – THE SLEEPING GIANT JUST WOKE UP! 🚨
Stop posting trash and look at the HARD DATA. While you were sleeping,
$INBS transformed from a "maybe" into a Revenue Machine:
1️⃣ REVENUE EXPLOSION: +48% YoY growth. Reader sales (the 'razor') up 104%. This isn't a hope story anymore, it’s a scaling business. 📈
2️⃣ CASH IS KING:
$9.4M fresh cash from the Jan placement. Institutional floor at
$2.14 is rock solid. Funding for the US FDA 510(k) expansion is SECURED.
3️⃣ TINY FLOAT / HUGE VOLATILITY: Annualized volatility at 353% with a tiny 1.2M float. This is a powder keg. Pre-market
$5.09 was just a warning shot.
4️⃣ FDA CATALYST: Clinical trials for the US market (H2 2026) are the ultimate endgame. Price target median is
$12.24 – that’s more than 100% upside from here!
Don't let the shorts fool you with daily noise. The fundamentals are screaming "Undervalued". We are coiled like a spring. Next stop: Gap fill to
$6.50 and then the moon!
